TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
Sports
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | United StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
UPSC | Exam ScheduleExam Mentor
Don't Miss
Advertisement

Pfizer withdraws application for Emergency Use Authorisation of Covid vaccine in India

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

Tribune News Service

Advertisement

New Delhi, February 5

Advertisement

Pfizer on Friday withdrew its application seeking grant of Emergency Use Authorisation (EUA) of its Covid vaccine in India after the regulators sought additional data.

Pfizer was the first to apply for EUA in India but has been repeatedly asked to update its data as the company never applied for any bridging studies here.

Under the Indian clinical trial rules, any company with a new drug or vaccine should apply for bridging studies in India to produce domestic safety data involving Indians.

Advertisement

Russia had very early on tied up with Dr Reddy’s Lab in Hyderabad to conduct bridging studies in India for Sputnik V vaccine.

Pfizer is learnt to have said it would meet the requirements listed by India’s Central Drugs Standards Control Organisation and consider re-submitting the application.

The UK was the first to license Pfizer vaccine.

Advertisement
Show comments
Advertisement